ZNF133

Across TCGA pan-cancer cohorts, ZNF133 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated ZNF133 data layer compared with 5 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF133 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF133 expression acts as an unfavorable survival marker, although some lineages such as LUAD and READ show a favorable association.

LIHC, KIRC, and COAD are the cancer types where ZNF133 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.431	0.652	<.001	110	view →
KIRC	DFS	Median	II,III,IV	0.411	0.632	<.001	88	view →
COAD	OS	Median	All	0.736	0.861	<.001	87	view →
LUAD	OS	Quartile	II,III,IV	0.706	0.335	<.001	37	view →
READ	OS	Tertile	All	1.000	0.843	.007	27	view →
BLCA	OS	Median	All	0.471	0.680	.019	26	view →
KICH	OS	Quartile	All	0.718	1.000	.012	26	view →
SCLC	OS	Tertile	II,III,IV	1.000	0.434	.013	14	view →
PRAD	DFS	Tertile	All	0.892	0.963	.005	14	view →
SKCM	DFS	Median	All	0.670	0.547	.006	13	view →
GBM	DFS	Median	All	0.388	0.184	.001	12	view →
ACC	DFS	Tertile	III,IV	0.813	0.362	.008	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

ZNF133–LIHC (DFS)

Open the LIHC breakdown →